224 related articles for article (PubMed ID: 33688929)
21. The contribution of N-terminal truncated cMyBPC to in vivo cardiac function.
Dominic KL; Choi J; Holmes JB; Singh M; Majcher MJ; Stelzer JE
J Gen Physiol; 2023 Jun; 155(6):. PubMed ID: 37067542
[TBL] [Abstract][Full Text] [Related]
22. Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management.
Patel PH; Nguyen M; Rodriguez R; Surani S; Udeani G
Cureus; 2021 Jan; 13(1):e12419. PubMed ID: 33542867
[TBL] [Abstract][Full Text] [Related]
23. Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.
Horváth B; Szentandrássy N; Veress R; Almássy J; Magyar J; Bányász T; Tóth A; Papp Z; Nánási PP
Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1239-1246. PubMed ID: 28940010
[TBL] [Abstract][Full Text] [Related]
24. Myosin from the ventricle is more sensitive to omecamtiv mecarbil than myosin from the atrium.
Shchepkin DV; Nabiev SR; Nikitina LV; Kochurova AM; Berg VY; Bershitsky SY; Kopylova GV
Biochem Biophys Res Commun; 2020 Aug; 528(4):658-663. PubMed ID: 32513536
[TBL] [Abstract][Full Text] [Related]
25. Cardiac myosin binding protein C insufficiency leads to early onset of mechanical dysfunction.
Desjardins CL; Chen Y; Coulton AT; Hoit BD; Yu X; Stelzer JE
Circ Cardiovasc Imaging; 2012 Jan; 5(1):127-36. PubMed ID: 22157650
[TBL] [Abstract][Full Text] [Related]
26. Enhanced cardiac function in Gravin mutant mice involves alterations in the β-adrenergic receptor signaling cascade.
Guillory AN; Yin X; Wijaya CS; Diaz Diaz AC; Rababa'h A; Singh S; Atrooz F; Sadayappan S; McConnell BK
PLoS One; 2013; 8(9):e74784. PubMed ID: 24058627
[TBL] [Abstract][Full Text] [Related]
27. Omecamtiv mecarbil attenuates length-tension relationship in healthy rat myocardium and preserves it in monocrotaline-induced pulmonary heart failure.
Lookin O; Kuznetsov D; Protsenko Y
Clin Exp Pharmacol Physiol; 2022 Jan; 49(1):84-93. PubMed ID: 34459025
[TBL] [Abstract][Full Text] [Related]
28. AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice.
Li J; Mamidi R; Doh CY; Holmes JB; Bharambe N; Ramachandran R; Stelzer JE
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32750038
[TBL] [Abstract][Full Text] [Related]
29. PKCepsilon increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo.
Xiao L; Zhao Q; Du Y; Yuan C; Solaro RJ; Buttrick PM
Biochemistry; 2007 Jun; 46(23):7054-61. PubMed ID: 17503784
[TBL] [Abstract][Full Text] [Related]
30. Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.
Nanasi P; Komaromi I; Gaburjakova M; Almassy J
Curr Med Chem; 2018; 25(15):1720-1728. PubMed ID: 29278207
[TBL] [Abstract][Full Text] [Related]
31. Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin.
Liu Y; White HD; Belknap B; Winkelmann DA; Forgacs E
Biochemistry; 2015 Mar; 54(10):1963-75. PubMed ID: 25680381
[TBL] [Abstract][Full Text] [Related]
32. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
[TBL] [Abstract][Full Text] [Related]
33. Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke.
Woody MS; Greenberg MJ; Barua B; Winkelmann DA; Goldman YE; Ostap EM
Nat Commun; 2018 Sep; 9(1):3838. PubMed ID: 30242219
[TBL] [Abstract][Full Text] [Related]
34. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
35. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
Psotka MA; Teerlink JR
Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
[TBL] [Abstract][Full Text] [Related]
36. Normal cardiac contraction in mice lacking the proline-alanine rich region and C1 domain of cardiac myosin binding protein C.
van Dijk SJ; Witt CC; Harris SP
J Mol Cell Cardiol; 2015 Nov; 88():124-32. PubMed ID: 26455481
[TBL] [Abstract][Full Text] [Related]
37. The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat.
Nagy L; Kovács Á; Bódi B; Pásztor ET; Fülöp GÁ; Tóth A; Édes I; Papp Z
Br J Pharmacol; 2015 Sep; 172(18):4506-4518. PubMed ID: 26140433
[TBL] [Abstract][Full Text] [Related]
38. Perspectives of a myosin motor activator agent with increased selectivity.
Nánási P; Komáromi I; Almássy J
Can J Physiol Pharmacol; 2018 Jul; 96(7):676-680. PubMed ID: 29792814
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylation of cardiac Myosin-binding protein-C is a critical mediator of diastolic function.
Rosas PC; Liu Y; Abdalla MI; Thomas CM; Kidwell DT; Dusio GF; Mukhopadhyay D; Kumar R; Baker KM; Mitchell BM; Powers PA; Fitzsimons DP; Patel BG; Warren CM; Solaro RJ; Moss RL; Tong CW
Circ Heart Fail; 2015 May; 8(3):582-94. PubMed ID: 25740839
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
